| Oct 29 |
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
|
| Oct 15 |
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
|
| Sep 17 |
Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug
|
| Sep 17 |
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
|
| Sep 5 |
Gold Moves Higher; Science Applications International Posts Upbeat Earnings
|
| Sep 5 |
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
|
| Sep 5 |
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
|
| Aug 16 |
Hoth and Aronnax partner for HT-KIT cancer therapy development
|
| Aug 15 |
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
|
| Jul 24 |
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
|
